Lifeworks Advisors LLC Takes Position in CVS Health Corporation $CVS

Lifeworks Advisors LLC bought a new position in CVS Health Corporation (NYSE:CVS) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,739 shares of the pharmacy operator’s stock, valued at approximately $412,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd increased its stake in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of CVS Health during the 4th quarter valued at approximately $26,000. Sankala Group LLC purchased a new position in shares of CVS Health in the fourth quarter valued at $28,000. Global Trust Asset Management LLC grew its holdings in shares of CVS Health by 344.8% in the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. bought a new stake in CVS Health in the fourth quarter worth $28,000. 80.66% of the stock is owned by institutional investors.

CVS Health Price Performance

Shares of CVS stock opened at $105.97 on Tuesday. The stock has a 50 day moving average price of $97.36 and a 200 day moving average price of $84.41. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $106.40. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $135.21 billion, a P/E ratio of 46.68, a P/E/G ratio of 1.02 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the company posted $2.25 EPS. CVS Health’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be issued a $0.665 dividend. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. CVS Health’s dividend payout ratio is presently 117.18%.

Analysts Set New Price Targets

CVS has been the subject of several research reports. Mizuho increased their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Weiss Ratings restated a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a report on Tuesday, July 7th. UBS Group lifted their price target on CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Finally, JPMorgan Chase & Co. boosted their price objective on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Twenty-one analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $103.64.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last ninety days. 0.85% of the stock is currently owned by insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.